title: Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris.
abstract: Thymosin-alpha1 (Talpha1) is indicated for the treatment of certain viral infections, including hepatitis B and C, and cancers, such as melanoma. In this paper, the fusion genes encoding human serum albumin (HSA) and Talpha1 with (rHSA-L-Talpha1) and without a linker peptide (rHSA-Talpha1) were constructed and overexpressed in P. pastoris. Through the process of ion interaction chromatography (Q-Sepharose F.F), hydrophobic interaction chromatography (Phenyl Sepharose HP) and affinity chromatography (Blue Sepharose F.F), the purity of fusion proteins was greater than 97%. In contrast to the reactivity of normal spleen cells to Con A, the data of in vitro murine spleen lymphocytes proliferation experiment suggested that spleen cells achieved a higher degree of T cell maturation after rHSA-L-Talpha1, rHSA-Talpha1 and Talpha1 treatments, respectively. Moreover, rHSA-L-Talpha1, rHSA-Talpha1 and Talpha1 can also antagonize dexamethasone-induced apoptosis of thymocyte sub-populations. In hydrocortisone-induced immunosuppression mice (in vivo experiments), after subcutaneous injections with two fusion proteins and Talpha1 for seven consecutive days, the net increment of body weight, the spleen index and the thymus index were significantly improved. Simultaneously, the increase in SOD level and the decrease in MDA level in plasma were observed. The pharmacokinetic data of rHSA-L-Talpha1 and rHSA-Talpha1 administered in rats showed an improved pharmacokinetic profile with a conspicuous prolonged half life. The analysis of bioactivity and pharmacokinetics suggested that fusion proteins rHSA-L-Talpha1 and rHSA-Talpha1 were new drug candidates.
authors.affiliation: College of Life Science and Technology, China Pharmaceutical University, Nanjing, People's Republic of China. jhchen@cpu.edu.cn
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Chen
authors.forename: Xin-Guo
authors.initials: XG
authors.lastname: Zhang
authors.forename: Yu-Tao
authors.initials: YT
authors.lastname: Jiang
authors.forename: Lu-Ying
authors.initials: LY
authors.lastname: Yan
authors.forename: Li
authors.initials: L
authors.lastname: Tang
authors.forename: Yi-Wei
authors.initials: YW
authors.lastname: Yin
authors.forename: Dai-Shuang
authors.initials: DS
authors.lastname: Cheng
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.forename: Min
authors.initials: M
authors.lastname: Wang
mesh_terms: D000447:Aldehydes / Q000097:blood; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D010843:Pichia; D015202:Protein Engineering; D051381:Rats; D017207:Rats, Sprague-Dawley; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics / Q000493:pharmacokinetics; D012709:Serum Albumin / Q000096:biosynthesis / Q000235:genetics*; D013482:Superoxide Dismutase / Q000097:blood / Q000235:genetics / Q000378:metabolism; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D000077596:Thymalfasin; D013947:Thymosin / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000235:genetics
chemical_list: D000447:Aldehydes; D011993:Recombinant Fusion Proteins; D012709:Serum Albumin; C015977:malealdehyde; D013947:Thymosin; D013482:Superoxide Dismutase; D000077596:Thymalfasin
references.citation: Sheng Wu Gong Cheng Xue Bao. 2005 Mar;21(2):254-8
references.pmid: 16013485
references.citation: J Viral Hepat. 2002 Jul;9(4):280-7
references.pmid: 12081605
references.citation: J Biosci Bioeng. 2000;89(1):55-61
references.pmid: 16232698
references.citation: Toxicology. 2009 Mar 29;257(3):113-6
references.pmid: 19150643
references.citation: Scand J Immunol. 2005 Jul;62(1):45-54
references.pmid: 16091124
references.citation: J Pharmacol Exp Ther. 2002 Nov;303(2):540-8
references.pmid: 12388634
references.citation: Ann N Y Acad Sci. 2000;917:868-75
references.pmid: 11268418
references.citation: World J Surg. 2005 Mar;29(3):264-70
references.pmid: 15706436
references.citation: Blood. 2004 Jun 1;103(11):4232-9
references.pmid: 14982877
references.citation: Biologicals. 2006 Mar;34(1):55-9
references.pmid: 16464610
references.citation: Arch Otolaryngol Head Neck Surg. 1989 Nov;115(11):1345-9
references.pmid: 2803715
references.citation: Clin Exp Immunol. 2004 Apr;136(1):95-103
references.pmid: 15030519
references.citation: Proc Natl Acad Sci U S A. 1972 Jul;69(7):1800-3
references.pmid: 4505657
references.citation: Int J Immunopharmacol. 2000 Dec;22(12):1057-66
references.pmid: 11137612
references.citation: Clin Exp Immunol. 2003 Dec;134(3):477-81
references.pmid: 14632754
references.citation: Protein Expr Purif. 2006 Mar;46(1):56-63
references.pmid: 16343940
references.citation: Immunopharmacol Immunotoxicol. 2001 Feb;23(1):75-82
references.pmid: 11322651
references.citation: Int Immunopharmacol. 2003 Aug;3(8):1145-50
references.pmid: 12860169
references.citation: Int J Immunopharmacol. 1997 Feb;19(2):59-66
references.pmid: 9278175
references.citation: Dig Dis Sci. 2000 Apr;45(4):690-6
references.pmid: 10759236
references.citation: Ann N Y Acad Sci. 2007 Sep;1112:326-38
references.pmid: 17495242
references.citation: Int J Immunopharmacol. 2000 Dec;22(12):1067-76
references.pmid: 11137613
references.citation: Int Immunopharmacol. 2002 Jan;2(1):39-46
references.pmid: 11789668
references.citation: Yeast. 2005 Mar;22(4):249-70
references.pmid: 15704221
references.citation: Chem Biol Interact. 2009 Aug 14;180(3):383-8
references.pmid: 19442654
references.citation: J Endocrinol. 2001 Jun;169(3):429-35
references.pmid: 11375112
references.citation: J Gastroenterol Hepatol. 2002 Apr;17(4):409-14
references.pmid: 11982721
references.citation: Int Immunopharmacol. 2003 Aug;3(8):1061-71
references.pmid: 12860163
references.citation: Expert Opin Biol Ther. 2004 Apr;4(4):559-73
references.pmid: 15102605
references.citation: Science. 1964 Feb 28;143(3609):965-6
references.pmid: 14090149
references.citation: Clin Biochem. 2005 Jun;38(6):540-7
references.pmid: 15885234
references.citation: Dev Comp Immunol. 2007;31(12):1264-77
references.pmid: 17459475
references.citation: Pharmacol Res. 2003 Mar;47(3):217-24
references.pmid: 12591017
references.citation: J Immunol. 2000 Feb 15;164(4):1768-74
references.pmid: 10657623
references.citation: Vet Res Commun. 2007 Oct;31(7):809-18
references.pmid: 17279464
references.citation: J Mol Recognit. 2005 Mar-Apr;18(2):119-38
references.pmid: 15565717
references.citation: Eur J Clin Invest. 2000 May;30(5):454-9
references.pmid: 10809906